Citi Appointed as Depositary Bank for Amryt Pharma’s ADR Programme

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Citi, acting through Citibank N.A., has been appointed by Amryt Pharma Plc (Amryt) “ a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases “ to act as depositary bank for its American Depositary Receipt (ADR) programme.

Amryts American Depositary Shares (ADS) trade on the Nasdaq Global Select market under the symbol AMYT. Each ADS represents five ordinary shares of the company. Amryts underlying ordinary shares are listed and trade on AIM, a market operated by the London Stock Exchange, under the symbol AMYT, and on Euronext Growth, a market regulated by Euronext Growth Market Dublin, under the symbol AYP.

Joe Wiley, CEO of Amryt, commented: Listing on Nasdaq is a very important milestone for Amryt and will provide us with the opportunity to improve underlying liquidity in our shares, target a wider investor audience and increase our analyst coverage. With nearly 70% of our shareholders based in North America, listing on Nasdaq is an important part of our shareholder engagement and development plans. Furthermore, we believe our Nasdaq listing will significantly assist our efforts to drive value for all our stakeholders.

Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: We look forward to supporting Amryts ADR programme and expanding the companys investor outreach through the expertise of our leading Investor Relations Advisory team and the breadth of our global equity distribution network.

For more information on Citis Depositary Receipt Services, visit www.citi.com/dr.

About Amryt www.amrytpharma.com

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

Amryts commercial business comprises two orphan disease products.

About Citi Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

Citi Media Contacts:

Susan Monahan

+44 (0) 20 7508 0786

[email protected]

Amryt Investor Contacts:

Rory Nealon, CFO

+353 1 518 0200

[email protected]